<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39378872</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-1645</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>08</Day></PubDate></JournalIssue><Title>The American journal of tropical medicine and hygiene</Title><ISOAbbreviation>Am J Trop Med Hyg</ISOAbbreviation></Journal><ArticleTitle>Operational Research to Support Rapid Evidence-Based Responses to Outbreaks: Learnings from COVID-19.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">tpmd230893</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.4269/ajtmh.23-0893</ELocationID><Abstract><AbstractText>During the COVID-19 pandemic, the need for making testing readily available was recognized as an important factor for individuals to help make informed decisions, including to isolate or seek care, and for policymakers to control transmission. Toward this end, FIND and the Access to COVID-19 Tools Accelerator funded 16 rapid operational research studies and one implementation project in Africa, the Caribbean, and Asia evaluating the utility, acceptability, and feasibility of different community-based SARS-CoV-2 testing approaches. Here, we discuss common factors and challenges encountered during study implementation. We note six key factors essential for success: 1) collaboration and partnerships; 2) buy-in of local stakeholders, including communities; 3) access to affordable supplies; 4) flexible financing; 5) effective approval systems; and 6) a skilled and motivated workforce. We also note various challenges that must be addressed to fully capitalize on these success factors. In particular, ethics committees are often not well equipped to assess operational research during outbreaks. Outbreaks, especially of novel pathogens, are unpredictable, and transmission dynamics are even more likely to change if the pathogen is prone to frequent mutations, such as SARS-CoV-2. Research that aims to evaluate strategies for curbing transmission must hence be easily and swiftly adaptable. This requires flexibility from researchers, funders, staff conducting the studies, and ethics and other approval committees. International guidelines for evaluating operational research protocols in outbreaks are needed to provide timely evidence to enable informed decisions by individuals, communities, and policymakers, thereby reducing both the human and the economic impact of outbreaks.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hoppe</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Global Health Security, FIND, Geneva, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Technical Strategy and Innovation, Elizabeth Glaser Pediatric AIDS Foundation, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dani</LastName><ForeName>Pallavi</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Global Health Security, FIND, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mwangoka</LastName><ForeName>Grace</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Biomedical Research and Clinical Trials, Ifakara Health Institute, Bagamoyo, Tanzania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vreden</LastName><ForeName>Stephen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Foundation for the Advancement of Scientific Research, Paramaribo, Suriname.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Breton</LastName><ForeName>Guillaume</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Technical Department, Solthis, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ateudjieu</LastName><ForeName>Jerome</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Health Research and Intervention, M. A. SANTE, Yaoundé, Cameroon.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nankabirwa</LastName><ForeName>Joaniter I</ForeName><Initials>JI</Initials><AffiliationInfo><Affiliation>Research Department, Infectious Diseases Research Collaboration, Kampala, Uganda.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sambo</LastName><ForeName>Júlia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Health Research Management &amp; Coordination, Instituto Nacional de Saude, Maputo, Mozambique.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masaba</LastName><ForeName>Rose</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Research, Elizabeth Glaser Pediatric AIDS Foundation, Nairobi, Kenya.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maparo</LastName><ForeName>Tatenda</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Access Program, Clinton Health Access Initiative, Harare, Zimbabwe.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sibeko</LastName><ForeName>Goodman</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Psychiatry and Mental Health, University of Cape Town, Cape Town, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Njouom</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Virology, Centre Pasteur of Cameroon, Yaoundé, Cameroon.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tchounga</LastName><ForeName>Boris</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Research, Elizabeth Glaser Pediatric AIDS Foundation, Yaoundé, Cameroon.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ssewanyana</LastName><ForeName>Isaac</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Laboratory Services, Central Public Health Laboratories, Kampala, Uganda.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chavula</LastName><ForeName>Chancy</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Diagnostics, Clinton Health Access Initiative, Lilongwe, Malawi.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nchimunya</LastName><ForeName>Lindiwe</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Diagnostics, Clinton Health Access Initiative, Lusaka, Zambia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Djikeussi</LastName><ForeName>Tatiana</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Research, Elizabeth Glaser Pediatric AIDS Foundation, Yaoundé, Cameroon.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Accellam</LastName><ForeName>Sam</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Global Health Security, FIND, Geneva, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory Services, Central Public Health Laboratories, Kampala, Uganda.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cairo</LastName><ForeName>Hedley</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Malaria Program, Ministry of Health Suriname, Paramaribo, Suriname.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walcott</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Microbiology, University Hospital Of The West Indies, Kingston, Jamaica.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khan</LastName><ForeName>Aamir J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Infectious Diseases, IRD Global, Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khan</LastName><ForeName>Shaukat</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Global Health Security, FIND, Geneva, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Global Diagnostic Teams, Clinton Health Access Initiative, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bausch</LastName><ForeName>Daniel G</ForeName><Initials>DG</Initials><AffiliationInfo><Affiliation>Global Health Security, FIND, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Trop Med Hyg</MedlineTA><NlmUniqueID>0370507</NlmUniqueID><ISSNLinking>0002-9637</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>12</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>9</Day><Hour>4</Hour><Minute>50</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>9</Day><Hour>4</Hour><Minute>50</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>8</Day><Hour>18</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39378872</ArticleId><ArticleId IdType="doi">10.4269/ajtmh.23-0893</ArticleId><ArticleId IdType="pii">tpmd230893</ArticleId></ArticleIdList></PubmedData></PubmedArticle>